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TABLE 1 Clinical Var
Female
Heart rate, beats/min
Walk distance, m
Age at study date, yrs
Age at repair, yrs
Previous atrial arrhythm
NYHA functional class
QRS duration, ms
BNP, pg/ml
ln BNP
LV-EDVi, ml/m2
LV-ESVi, ml/m2
LV ejection fraction, %
RV-EDVi, ml/m2
RV-ESVi, ml/m2
RV ejection fraction, %
Pulmonary regurgitant
LA area, cm2
LA volume index, ml/m
RA area, cm2
RA volume index, ml/m
Lambda
T1 pre-gadolinium, ms
T1 15 min post-gadolin
Extracellular volume, %
Values are n (%), mean 
BNP ¼ B-type brain natr
systolic volume index; NYH
index; TOF ¼ tetralogy of
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P U B L I S H E D B Y E L S E V I E RLETTER TO THE EDITORDiffuse LV Myocardial Fibrosis and its Clinical
Associations in Adults With Repaired
Tetralogy of FallotWe recently investigated left ventricular (LV)
myocardial ﬁbrosis using the extracellular volume
fraction (LV-ECV) and sought associations with
other signs of cardiovascular dysfunction such as
systolic dysfunction, exercise intolerance, and
arrhythmia to investigate its potential role as a risk
factor for complications after tetralogy of Fallot
(TOF) repair.
We prospectively studied 52 TOF consented adults
(without implanted devices or renal insufﬁciency)
and 22 control subjects with magnetic resonance
(1.5-T) for LV and right ventricular (RV) volume/iables and Appropriate Comparisons
Control Subjects
(n ¼ 22)
TOF Subjects
(n ¼ 52) p Val
9 (41) 24 (46) 0.6
62  8 69  10 0.0
639  79 507  109 <0.0
39.4  11.9 40.0  14.0 0.8
ia
19 [18] 57 [72] 0.0
2.92  0.61 4.12  0.90 <0.0
80  10 84  15 0.2
25  6 33  12 0.0
69  6 61  9 <0.0
88  14 131  39 <0.0
33  8 66  25 <0.0
62  6 50  8 <0.0
fraction, %
22.3  4 21.1  7 0.2
2 52  11 43  29 0.14
23.1  4.0 26.8  9.0 0.0
2 50  12 58  32 0.2
0.445  0.041 0.471  0.050 0.0
1,155  53 1,123  124 0.2
ium, ms 508  45 488  62 0.17
26.1  2.8 28.2  3.9 0.0
SD, or median [interquartile range].
iuretic peptide; ECV ¼ extracellular volume fraction; LA ¼ left atrial; LV ¼ left ventricular; L
A ¼ New York Heart Association; RA ¼ right atrial; RV ¼ right ventricular; RV-EDVi ¼ right ve
Fallot.function and atrial volumes (area-length method). A
midventricular Look-Locker sequence (16 to 21 phases)
was prescribed perpendicular to the septum before
and 3, 7, and 15 min after Omniscan contrast
(Novation LLC, GE Healthcare, Princeton, New Jersey)
injection (0.15 mmol/kg). LV myocardium and blood
pool were contoured (QMass, Medis Medical Imaging
Systems, Leiden, the Netherlands). Time-signal in-
tensity curves were used to quantify T1 for myocar-
dium and blood pool through exponential ﬁtting, and
its reciprocal R1. The linear slope of R1 for myocar-
dium versus blood deﬁned lambda. Multiplying by
(1  hematocrit/100) gave LV-ECV. For 5 subjects,
faulty baseline T1 values required an imputation us-
ing the mean for the cohort.
LV-ECV was greater in TOF than in control subjects
(28.2  3.9% vs. 26.1  2.8%, p ¼ 0.026) and higher in
womenthan inmen (30.03.8%vs.26.53.3%,p¼0.001
inTOFand28.5 1.4%vs.24.42.2%,p<0.001 incontrol
subjects). Other differences are shown in Table 1. Amongue
TOF ECV <30%
(n ¼ 37)
TOF ECV $30%
(n ¼ 15) p Value
8 14 (38) 10 (67) 0.073
05 68  10 71  9 0.26
01 533  96 437  117 0.007
6 36.6  11.8 48.3  15.7 0.005
6 [32] 3 [6] 0.024
4 (14) 5 (56) 0.020
1.3  0.7 2.4  1.1 0.008
140  27 170  19 0.007
17 49 [38] 189 [259] 0.001
01 3.87  0.66 4.86  1.15 0.001
7 159  38 151  25 0.45
05 64  30 61  17 0.68
01 61  9 60  9 0.75
01 247  92 245  72 0.92
01 123  55 128  49 0.73
01 51  9 49  7 0.33
38  36 42  40 0.32
8 19.9  5.2 21.1  7.4 0.077
37  18 56  44 0.027
78 25.8  9.1 26.8  9.1 0.24
3 53  32 72  29 0.054
38 0.448  0.040 0.523  0.031 <0.001
5 1,127  109 1,116  157 0.78
497  50 464  81 0.077
26 26.3  2.3 32.9  2.9 <0.001
V-EDVi ¼ left ventricular end-diastolic volume index; LV-ESVi ¼ left ventricular end-
ntricular end-diastolic volume index; RV-ESVi ¼ right ventricular end-systolic volume
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87TOF subjects, age correlated positively with LV-ECV in
TOF subjects (r ¼ 0.529, p < 0.001), but not in control
subjects (r¼0.142). LV-ECV correlatedwith age at repair
(r¼ 0.487, p< 0.001), QRS duration (r ¼ 0.521, p ¼ 0.002),
6-min walk distance (r ¼ 0.417, p < 0.004), B-type
brain natriuretic peptide (BNP) (r ¼ 0.548, p < 0.001),
left atrial (r ¼ 0.363, p ¼ 0.008), and right atrial volume
(r ¼ 0.326, p ¼ 0.018).
Fifteen TOF subjects (29%, 95% conﬁdence inter-
val: 17% to 41%) had LV-ECV values $30% (Table 1).
These differed by age, age at repair, number of pre-
vious surgeries, previous atrial arrhythmia, QRS
duration, 6-min walk distance, BNP, and left atrial
volume. There was no difference in ventricular size,
function, or pulmonary valve regurgitation fraction.
Late gadolinium enhancement (LGE) showed
small septal foci in 5 subjects, and in the inferior/
inferolateral wall in 4 (excluding the RV/LV junction).
Three of 5 subjects had septal LGE in the LV-ECV
plane. All regions were very small and had no ap-
preciable impact on the overall results, whether
included or excluded.
Forty-eight TOF subjects were followed for 3.5  1.5
years. Of those with LV-ECV $30%, 5 (33%) had sig-
niﬁcant clinical events (2 new atrial arrhythmia and 3
cardiovascular deaths) versus only 2 subjects (atrial
arrhythmia) in those with LV-ECV <30% (p ¼ 0.024).
Thus, LV myocardial ﬁbrosis was found in >25% of
subjects and associated with other adverse clinical
markers and outcomes. These ﬁndings agree with
other research showing ﬁbrosis as a byproduct of
adverse ventricular loading and contributor to clinical
outcome (1,2). Therefore, efforts to prevent and treat
ﬁbrosis should be renewed, including earlier inter-
vention and consideration of pharmacotherapeutic
options that may attenuate ﬁbrogenesis. Clinical
management should focus equally on preventing and
treating ﬁbrosis as on anatomic defect repair.
A higher percentage of subjects with LV ﬁbrosis
were identiﬁed by LV-ECV than with LGE, consistent
with ﬁndings of other studies (3). LV-ECV did not
differentiate those with systolic dysfunction, also
similar to others (2), implying that ﬁbrosis precedes
dysfunction. Other myocardial function metrics, in-
cluding strain, may be more sensitive to early LV
ﬁbrosis. Chronic volume and pressure loading of the
RV are undoubtedly inciting factors of LV dysfunction
over long periods of time. Future longitudinal studies
could determine gradual changes in response to RV
pressure and/or volume loading.
Although it has been shown to be predictive of
events in other populations, the potential of LV-ECV in
surveillance of future events needs conﬁrmation.Fibrosis in the RV by LGE (1) and T1mapping (2) has also
been shown, but we did not quantify this in the thin-
walled RV with our methods. Consistent with other
studies (4,5), LV-ECV was higher in female subjects
(both groups), meriting future investigation.
Therefore, LV ﬁbrosis should be considered a sig-
niﬁcant contributor to an adverse natural history af-
ter TOF repair. With further validation, LV-ECV
measurement may support future investigation of
both the etiology and treatment of TOF subjects.Craig S. Broberg, MD, MCR*
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